JAK kinases are now well-established targets in immunology, but the class has always had safety concerns hanging over it. The safety issues were exacerbated by a recent FDA decision to expand the black box warnings for the class for major cardiovascular events. Inhaled, lung-restricted JAK inhibitors have been of interest because they could [...]
1 minute read
Jan. 17, 2022
Respiratory Case Study: An Inhaled JAK Inhibitor from GSK
“compound 54c”
inhaled JAK inhibitor reduced AO metabolism in lung from kinase-focused screening and SBDD Journal of Medicinal Chemistry GlaxoSmithKline, Stevenage, UK
Reviewer: